Predicting sPTB Early: What Do We Do Now?
The objective if this discussion is to look at some of the implications of having an objective predictor. What do we do differently? In what ways can this make a greater difference in our fight against preterm birth? We also need to address some of the uncertainties that exist when we know a woman is at risk for preterm birth.
Predicting sPTB Early: What Do We Do Now?
With the tools available to us today, physicians are unable to predict the large majority of women who will eventually deliver preterm. Now we have a proteomic predictor – which also provides the beginning of greater understanding of pathways.
The objective if this discussion is to look at some of the implications of having an objective predictor. What do we do differently? In what ways can this make a greater difference in our fight against preterm birth? We also need to address some of the uncertainties that exist when we know a woman is at risk for preterm birth.
Tebipenem HBr cUTI trial ends early after meeting efficacy goals
May 28th 2025GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.
Read More
